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Strengths and limitations of this study
 ► This systematic review will comprehensively evalu-
ate the validity of selected major cardiovascular di-
agnoses (stroke, acute coronary syndrome and heart 
failure) in electronic health record (EHR) databases 
used in the provision of primary and secondary clin-
ical care in Europe by searching five bibliographic 
databases and two grey literature sources with no 
language or date restrictions.
 ► The Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement will be fol-
lowed ensuring this systematic review provides 
high-quality scientific results.
 ► There may be heterogeneity in the results produced 
by our systematic review due to differences in EHR 
design and use between countries, in particular the 
relevance of our findings to countries outside of 
Europe requires further evaluation.
AbStrACt
Introduction Cardiovascular diseases (CVDs) are among 
the leading causes of death globally. Electronic health 
records (EHRs) provide a rich data source for research on 
CVD risk factors, treatments and outcomes. Researchers 
must be confident in the validity of diagnoses in EHRs, 
particularly when diagnosis definitions and use of EHRs 
change over time. Our systematic review provides an up-
to-date appraisal of the validity of stroke, acute coronary 
syndrome (ACS) and heart failure (HF) diagnoses in 
European primary and secondary care EHRs.
Methods and analysis We will systematically review 
the published and grey literature to identify studies 
validating diagnoses of stroke, ACS and HF in European 
EHRs. MEDLINE, EMBASE, SCOPUS, Web of Science, 
Cochrane Library, OpenGrey and EThOS will be searched 
from the dates of inception to April 2019. A prespecified 
search strategy of subject headings and free-text terms 
in the title and abstract will be used. Two reviewers will 
independently screen titles and abstracts to identify 
eligible studies, followed by full-text review. We require 
studies to compare clinical codes with a suitable reference 
standard. Additionally, at least one validation measure 
(sensitivity, specificity, positive predictive value or negative 
predictive value) or raw data, for the calculation of a 
validation measure, is necessary. We will then extract 
data from the eligible studies using standardised tables 
and assess risk of bias in individual studies using the 
Quality Assessment of Diagnostic Accuracy Studies 2 
tool. Data will be synthesised into a narrative format and 
heterogeneity assessed. Meta-analysis will be considered 
when a sufficient number of homogeneous studies are 
available. The overall quality of evidence will be assessed 
using the Grading of Recommendations, Assessment, 
Development and Evaluation tool.
Ethics and dissemination This is a systematic review, 
so it does not require ethical approval. Our results will be 
submitted for peer-review publication.
PrOSPErO registration number CRD42019123898
IntrOduCtIOn
rationale
Stroke, acute coronary syndrome (ACS) and 
heart failure (HF) are the three cardiovas-
cular (CV) conditions, which substantially 
contribute to morbidity and mortality. Isch-
aemic heart disease followed by stroke have 
been the global leading causes of death for 15 
years, and in 2016 accounted for 15.2 million 
deaths.1 Also in 2016, worldwide more than 
13 million people were estimated to have 
suffered a stroke2 with healthcare expendi-
ture on stroke estimated to be 3%–5%.3–5 
An estimated 26 million people are living 
with HF,6 a chronic condition with acute 
episodes. HF is estimated to account for 
1%–2% of healthcare expenditure in Europe 
and the USA.7 Added to the complication of 
estimating the burden of CV conditions is 
changes to definitions; the fourth universal 
definition of myocardial infarction (MI) was 
issued in 2018.8
Increases in the incidence and prevalence 
of CV conditions are in part due to an ageing 
population,9 but also due to modifiable risk 
factors, such as smoking, unhealthful diet 
and lack of physical exercise, and non-modifi-
able risk factors, such as sex and ethnicity.10 A 
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Table 1 Provisional list of ICD-9 and ICD-10 codes 
included in diagnoses of interest
Diagnosis ICD-9 ICD-10
Stroke 430, 431, 432, 433, 
434
I60, I61, I62, I63, I64
Acute coronary 
syndrome
410, 411 I20.0, I21, I22, I24, 
I49
Heart failure 428 I11.0, I13.0, I13.2, I50
ICD, International Classifications of Disease.
range of factors, such as pollution, infections, emotional 
stress and physical exertion, can also trigger acute CV 
events particularly in those with pre-existing cardiovas-
cular disease (CVD).11–13
Electronic health record (EHR) databases are derived 
from clinical care records and contain longitudinal patient 
data on diagnoses, treatment and other clinically relevant 
variables, such as smoking. Administrative databases were 
developed for financial and management purposes to allo-
cate funding or billing of insurance claims. While both are 
types of computerised health-related data that have been 
widely used for research, they are quite distinct. In partic-
ular, the completeness and accuracy of the morbidity data 
may differ in the two types of data because of the very 
different reasons why the data were recorded in the first 
place. In settings where both clinical and administrative 
data are available, results from some studies suggest the 
quality of administrative data is lower.14 15
High-quality EHR-based research depends on correct 
classification of cases and non-cases. Several system-
atic reviews have previously appraised the validation of 
specific European EHRs16–18 as well as specific conditions 
recorded within EHRs, including CVD.19–23 The previous 
systematic reviews on the validity of CVD diagnoses 
included EHRs, along with administrative databases and 
vital registration databases. McCormick et al reported that 
the positive predictive value (PPV) of stroke diagnosis 
ranged from 32% to 98%, with the majority of included 
studies using administrative data from North America,22 
while Woodfield et al identified PPVs of >70% for stroke 
based on the results that included a greater proportion 
of studies from Europe,20 where EHRs are widely used. 
McCormick et al’s review of HF diagnosis validity obtained 
PPVs ranging from 17% to 100% but only contained four 
studies outside of North America.23
Aim and objectives
The aim of our systematic review is to provide an up-to-
date appraisal of the validity of stroke (and its subtypes), 
ACS (including MI and other ACS) and HF diagnoses in 
adults focused on European EHRs used in primary and 
secondary care. Our objectives are to:
1. Summarise and pool estimates of the sensitivity, spec-
ificity, PPV and negative predictive value (NPV) of 
stroke, ACS and HF diagnoses compared with a suit-
able reference standard.
2. Determine whether estimates differ by study popula-
tion, validation method, data source, diagnosis and 
time period.
MEthOdS
This protocol has been prepared using the Preferred 
Reporting Items for Systematic Reviews and Meta-Anal-
yses Protocols guidelines.24
Eligibility criteria
We used the PICOS (Population, Intervention, Compar-
ator, Outcomes and Study design) framework to 
formulate the research question and eligibility criteria for 
our review, but adapted this to replace ‘Intervention’ with 
‘Index test’, the modification recommended for system-
atic reviews of diagnostic test accuracy.25 This modifica-
tion was chosen as it is the closest resemblance to the 
validation of EHRs.
Population
Eligible studies will include records of adults aged 16 years 
or older from any European primary or secondary care 
national or the regional EHR database. We will exclude 
studies that validate administrative (insurance claims or 
billing) databases, disease registries or vital registration 
systems, as well as studies that validate locally held data-
bases. EHRs and administrative databases collect data 
for different purposes and may differ in accuracy, we are 
interested in the validity of EHRs used in clinical settings. 
The comprehensive data capture methods used to popu-
late disease registries mean that these datasets are often 
used as the gold standard in validation of EHRs so would 
be unsuitable to include in our validation estimates. 
Vital registration systems only capture deaths so unless 
combined with EHRs, the data is not by itself useful in 
non-mortality-related research. Finally, data from locally 
held databases are unlikely to be captured in centralised 
EHRs used in research and therefore validation results 
are not informative for researchers.
Index test
We are interested in records with clinical codes, for 
example, International Classification of Primary Care 
(ICPC) or International Classifications of Disease (ICD), 
which identify a diagnosis of stroke (and its subtypes), 
ACS (including MI and other ACS) or HF in primary 
or secondary care EHRs. The ICD-9 and ICD-10 codes, 
we assume studies, will include (and which we look to 
validate) in their stroke, ACS and HF definitions are 
presented in table 1.
Comparator
To be included, studies must have validated against an 
internal or external reference standard. Eligible external 
reference standards include manual review of medical 
records, patient or clinical questionnaire, or compar-
ison with an independent second database. Internal 
within database comparison includes validation against a 
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diagnosis algorithm or comparison of clinical codes with 
anonymised free text.
Outcome
Studies must either report (1) at least one of the following 
validation estimates; sensitivity, specificity, PPV and NPV 
or (2) data which allows at least validation estimates to be 
calculated.
Study design
We will include any type of study from any time period 
published in any language that includes the validation of 
the recording of stroke, ACS or HF diagnoses in an EHR 
database, regardless of if this was the main objective of 
the study.
Information sources
To review published and in-process citations the following 
databases will be searched from inception to April 2019; 
MEDLINE, EMBASE, SCOPUS, Web of Science and 
Cochrane Library. Using OpenGrey and EThOS, we will 
search for the relevant grey literature. Bibliographies of 
national EHR databases used for research will also be 
searched.
Search strategy
The search strategy will include subject heading terms 
and free text (title and abstract) for the concept of acute 
CV events using the synonyms of stroke, ACS and HF 
as well as the concepts of EHRs and validation. We will 
limit our search to studies conducted using European 
EHRs. Provisional search terms have been developed for 
MEDLINE (online supplementary appendix 1), and once 
finalised will be transcribed into corresponding searches 
for the other aforementioned information sources. We 
will also review the reference list of other relevant system-
atic reviews identified during the screening process as well 
as of articles included in our review to identify further 
potentially relevant studies.
Study records
Data management
Citations from the searched databases will be exported 
into Endnote X9. Electronic deduplication of records will 
be conducted, followed by manual deduplication where 
necessary.
Selection process
For the initial screening stage, two authors (JAD and RM) 
will independently review all titles and abstracts to assess 
whether they fulfil the eligibility criteria for inclusion. To 
reduce the risk of missing potentially relevant studies, 
reviewers will adopt a lenient approach for this first level 
of screening including any study that validate stroke, ACS 
or HF diagnoses in EHRs. Full-text articles for studies that 
meet the review criteria will be obtained and reviewed 
by the two authors (JAD and RM). The reasons for rejec-
tion of articles during the full-text screening process will 
be noted according to a hierarchical list: (1) could not 
obtain full text, (2) did not conduct validation, (3) dupli-
cate study, (4) wrong outcome, (5) wrong index (ie, not a 
primary or secondary care EHR in Europe), (6) not a suit-
able comparator or (7) no validation estimate or insuf-
ficient data to calculate. Any discrepancies at either the 
initial screening or full-text screening will be discussed by 
the two reviewers, with a third author (CW-G) consulted 
when necessary.
Data collection process
To extract information for each study selected for final 
inclusion, data extraction tables will be piloted by the 
two authors (JAD and RM) for three studies with changes 
made, if required. We will then dual extract data from 
a further 10% of studies using the finalised template. If 
there are any significant discrepancies between the two 
reviewers, then we will conduct parallel data extraction 
for a further 10% of studies, again checking for discrep-
ancies. This process will be repeated until no further 
discrepancies occur, at which stage the remaining data 
extraction will be completed by the single reviewer (JAD). 
At each stage, the third author (CW-G) will be consulted 
when the two reviewers cannot resolve discrepancies.
data items
Similar to our search strategy, we will use the PICOS 
framework to systematise the extraction of data from each 
study. We will use a standardised template containing 
information on each of the following five domains:
1. Population: participants, age and sex, inclusion and 
exclusion criteria.
2. Index test: EHR country, EHR name, EHR setting (pri-
mary or secondary care), EHR coding system (ICPC, 
ICD, etc), EHR coverage (regional or national), diag-
noses validated including whether incident or preva-
lent, specific diagnoses codes validated.
3. Comparator: method of validation, description of 
method.
4. Outcome: number of participant diagnoses planned, 
number of diagnoses conducted, measures of validity 
and raw data to calculate measures of validity.
5. Study characteristics: authors, publication year, lan-
guage, study design, study period, main aim of the 
study (validation or not validation).
Outcomes and prioritisation
The outcome is any validation estimate of stroke 
(including all subtypes), ACS (MI or other ACS) or HF. 
The study has no secondary outcomes.
risk of bias in individual studies
To assess bias, we will use a tailored version of the Quality 
Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) 
tool, which is used for assessing diagnostic accuracy 
studies,26 based on the previous modifications made for 
assessing the validity of diagnostic coding in EHRs.20 21 
We will consider bias in each of the domains included in 
QUADAS-2; patient selection, index test, reference stan-
dard and flow and timing. In the context of our review, 
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index test translates to the clinical codes validated. We 
will produce a summary risk of bias figure, as well as an 
additional table explaining each judgement.
Two authors (JAD and RM) will independently pilot 
the tailored QUADAS-2 tool, assessing bias in three of 
the included studies. Any necessary changes will be made 
to the tool and dual assessment by the two reviewers 
will be done with the finalised tool for a further 10% 
of studies. If there are significant discrepancies, we will 
continue parallel risk of bias assessment for another 10% 
of studies, repeating the process until no further discrep-
ancies occur. Assessment of the remaining studies will be 
completed by the single reviewer (JAD). At each stage, 
the third author (CW-G) will be consulted when the two 
reviewers cannot resolve discrepancies
data synthesis and metabias(es)
We will describe key study characteristics and use a narra-
tive synthesis and forest plots to summarise the validity 
of each of stroke, ACS and HF diagnoses in European 
primary and secondary care EHRs. The I2 statistic will 
our guide judgements about the level of statistical hetero-
geneity between the studies. We will use the Cochrane’s 
suggested guide to grade the heterogeneity as a low 
(0%–40%), moderate (30%–60%), substantial (50%–
90%) or considerable (75%–100%) obtained from the 
I² statistic.27 If there is the sufficient number of studies 
selected, we will explore the reasons for heterogeneity. We 
will compare heterogeneity before and after removing the 
studies that deemed to be at a high risk of bias overall and 
by subgroups of: (1) study populations, that is, specific 
demographic or clinical groups, (2) validation method, 
(3) data source, that is, primary care and secondary care 
EHRs, (4) specific diagnosis, that is, incident or prevalent 
and stroke or ACS subtype and (5) variation in validity 
estimates over time.
We will consider conducting meta-analyses for each CV 
condition to calculate pooled effect estimates for sensi-
tivity, specificity, PPV and NPV if studies are sufficiently 
homogeneous. Meta-analyses would be conducted by 
the aforementioned subgroups. Our choice of a fixed or 
random effects model would also be guided by the level of 
heterogeneity, with random effects meta-analysis methods 
followed if there is substantial heterogeneity.
Confidence in cumulative evidence
Two reviewers (JAD and RM) will independently use the 
Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE) tool28 to judge the certainty of 
cross-study evidence for the validity of diagnoses in EHRs 
and their use in research. Any discrepancies between the 
two reviewers’ judgements will be discussed and resolved, 
if necessary consulting the third author (CW-G). We 
will examine stroke, MI and HF diagnoses in EHRs for; 
overall risks of bias, inconsistency, indirectness, impreci-
sion and publication bias with the production of funnel 
plots. The strength of evidence will be categorised as 
high, moderate, low and very low. Our judgements will be 
presented in a summary of findings table.
Patient and public involvement
Patients and/or public were not involved in this system-
atic review.
dISCuSSIOn
This systematic review will provide an up-to-date assess-
ment of the validity of primary and secondary care EHRs 
used for stroke, ACS and HF research. To our knowledge, 
this will be the first systematic review to focus solely on the 
validity of CVD diagnoses in EHRs. Previous systematic 
reviews have included EHRs along with administrative 
databases and vital registration databases. Each of these 
data sources has a different primary purpose, which in 
turn will impact the validity of the systems. One previous 
systematic review of MI diagnoses identified the accuracy 
for vital registration databases was lower (all PPVs≤59%) 
than the hospitalisation data (three-quarters of studies 
PPV >59%).21 However, hospitalisation grouped EHRs 
and administrative databases together, so it is unclear if 
the one-quarter of studies with a PPV ≤59% differed by 
data source to those with higher PPVs.
Our systematic review will also serve to update several 
aspects covered by the previous systematic reviews vali-
dating CVD diagnoses. McCormick et al’s 2010 review of 
MI diagnoses only identified three studies that validated 
the ICD-10 coding.21 while Rubbo et al’s 2014 review iden-
tified eight studies.19 The majority of European countries 
implemented ICD-10 in the late 1990s. Our search run in 
April 2019 aims to identify more recent studies validating 
ICD-10 CVD diagnoses, the results of which are most 
relevant to today’s research. In the majority of studies 
included in the previous systematic review of HF diag-
noses, conducted in 2010, sensitivity was <69%.23 Only 
one of the three included European studies reported 
sensitivity, this was 43%.29 With an increase in the preva-
lence of HF,6 and therefore accompanying public health 
research, we hypothesise that more studies validating HF 
diagnoses in EHRs will have been published between 
2010 and 2019, the results of which will inform current 
HF research. Similarly, previous systematic reviews vali-
dating stroke diagnoses identified variation in accuracy 
by stroke subtype,20 22 with the inclusion of up-to-date 
studies, we aim to analyse temporal changes in validity 
estimates with the assumption that more recent studies 
should have higher and more consistent estimates across 
stroke subtype. We also aim to present results for ACS 
other than MI, such as unstable angina which have not 
been included in any previous systematic review.
Our systematic review benefits from searching multiple 
databases with no language barriers, compared with the 
previous systematic reviews of CVD diagnoses, which 
either only searched 1–2 databases or only included 
English language studies. There are some limitations to 
our systematic review. First, by aiming to validate EHRs, 
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rather than broader computerised health-related data-
sets, we have limited our review to Europe where EHRs 
operate nationally or covering nationally representative 
populations with widespread use in research. Conse-
quently, our findings will not be applicable to administra-
tive databases, also commonly used in research. Second, 
our results will not necessarily be applicable to countries 
outside of Europe using EHRs, if the design and utility 
of the EHRs differ. Lastly, previous systematic reviews on 
CVD diagnoses have been unable to conduct meta-anal-
yses due to the level of heterogeneity identified in their 
results. We hope that by limiting our systematic review to 
EHRs in Europe, many of which are set up and operated 
in similar ways, the level of heterogeneity between the 
studies will be reduced. However, we will still be limited by 
variation in the reference standard used and differences 
in the codes included in validation. Therefore, it may not 
be possible to conduct any meta-analysis.
Overall, our systematic review should provide useful 
and up-to-date findings to inform researchers on the 
validity of using EHRs in their research.
EthICS And dISSEMInAtIOn
Important protocol amendments will be documented 
and a justification for deviating from the original protocol 
provided in a protocol addendum. The findings of this 
review will be submitted to a peer-reviewed journal.
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